GTS Securities’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-386,300
Closed -$6.96M – 3813
2024
Q3
$6.96M Sell
386,300
-83,000
-18% -$1.45M 0.02% 689
2024
Q2
$7.63M Sell
469,300
-245,400
-34% -$3.78M 0.02% 621
2024
Q1
$10.1M Buy
714,700
+471,900
+194% +$5.95M 0.02% 505
2023
Q4
$2.53M Buy
242,800
+13,000
+6% +$121K ﹤0.01% 1488
2023
Q3
$2.34M Buy
+229,800
New +$2.14M ﹤0.01% 1410

Other funds holding TEVA

GTS Securities's TEVA Position: Q2 2026 in Review

GTS Securities sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2026, closing a stake of 46,218 shares — an estimated $1.39M sold.

GTS Securities first reported a position in TEVA in Q2 2023 and held it in 10 quarters. The position peaked at $14.5M in Q1 2024. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • GTS Securities reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 46,218 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $1.39M.
  • GTS Securities first reported a position in Teva Pharmaceutical Industries Limited in Q2 2023 and held it in 10 quarters.
  • GTS Securities's Teva Pharmaceutical Industries Limited position peaked at $14.5M in Q1 2024.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.